Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fasting Conditions

NCT00616681 is registered in ClinicalTrials.gov with Roxane Laboratories as lead sponsor.

NCT NCT00616681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00616681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fasting Conditions
Lead sponsor
Roxane Laboratories
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2004
Completion date
July 31, 2004
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, seizures